公司資料
REGENXBIO Inc. 股價、新聞與催化劑
- 股票代碼:
- RGNX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.88 USD (-1.87%)
收盤價
最後更新: 2026年9月21日
337M USD
市值
股價為何變動
截至 2026年9月21日，RGNX 下跌 1.87%，收於 $7.88。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
REGENXBIO is a gene-therapy company focused on adeno-associated virus platform programs and rare diseases. Its story is built around platform delivery and the commercialization of gene-based medicines.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, REGENXBIO sits in gene therapy.
商業模式特徵
The company depends on clinical validation, manufacturing execution, and the ability to create durable gene-therapy value.
生技產業定位
REGENXBIO is a high-catalyst gene-therapy name whose valuation is tied to platform and clinical progress.
未來催化劑
- REGENXBIO's catalysts are its ocular gene-therapy programs and the broader rare-disease pipeline, with the market wanting proof the platform still has staying power. The next update matters if it shows the gene-therapy franchise can keep advancing.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。